targeted therapy

  •   George Lundberg, MD

    Each person with cancer has unique biomarkers that may determine how well specific treatments might work for them. Learn more from this website all about biomarkers, prepared by the National Cancer Institute.

    .

  •   George Lundberg, MD

    The nonprofit National Comprehensive Cancer Network (NCCN) publishes guidelines for patients to learn more about their diagnosis and their treatment options. Here is their 2022 update for acute myeloid leukemia.

    .

  •   George Lundberg, MD

    The nonprofit National Comprehensive Cancer Network (NCCN) publishes guidelines for patients to learn more about their diagnosis and their treatment options. Here is their 2022 update for small cell lung cancer.

    .

  •   George Lundberg, MD

    The nonprofit National Comprehensive Cancer Network (NCCN) publishes guidelines for patients to learn more about their diagnosis and their treatment options. Here is their 2022 update for cervical cancer.

    .

  •   George Lundberg, MD

    The nonprofit National Comprehensive Cancer Network (NCCN) publishes guidelines for patients to learn more about their diagnosis and their treatment options. Here is their 2022 update for kidney cancer.

    .

  •   George Lundberg, MD

    Reported in Healio: After decades of little or no progress, many new clinical trials testing targeted and immunotherapy drugs—especially in combinations—are showing that they have real value in treating primary liver cancer (hepatocellular carcinoma).

    .

  •   George Lundberg, MD

    This scientific review paper published in the journal Signal Transduction and Targeted Therapy discusses recent research into newer medications that show promise as targeted therapies for some cases of primary hepatocellular carcinoma, following molecular testing.

    .

  •   George Lundberg, MD

    Article from OncLive curated by Editor in Chief George Lundberg, MD, who notes: 

    A new study shows that the drug pembrolizomab significantly prolongs survival in patients with metastatic melanoma, regardless of whether their tumors have mutations in the BRAF gene or if they’ve had prior treatment with targeted therapy.

    Go to full article published by OncLive.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research highlight from Nature Reviews Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    This year’s virtual meeting of the American Society of Clinical Oncology featured presentations on several different targeted therapies that appear to provide improved outcomes for lung cancer patients.

    Go to full research highlight published by Nature Reviews Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   Emma Shtivelman, PhD

    Excerpt from OncLive:

    “As a medical oncologist and investigator, Rinath M. Jeselsohn, MD, focuses on the detection and clinical implications of ESR1 mutations in estrogen receptor–positive breast cancer. She is a member of the research team in the lab of Myles A. Brown, MD, at Dana-Farber Cancer Institute in Boston, Massachusetts, where investigators are seeking to elucidate the factors underlying the mechanisms of hormone responsiveness, particularly steroid hormone receptors, in human cancers.

    “Jeselsohn, who has led numerous studies into ESR1 mutations, discussed the field in an interview with OncologyLive®.”

    Go to full article published by OncLive on Aug 3, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.